Starting stock price: $0.72
Ending stock price: $1.42
Percent Change: 97.22%
Details: Nexmed is using NexACT--it's transdermal drug delivery technology--to create therapies that can be delivered directly through the skin. The company is developing treatments for sexual disorders and nail fungus. In 2007 Nexmed completed patient enrollment in two Phase III studies for it's anti-fungal product, and filed an NDA for an erectile dysfunction treatment.
NexMed taps Berman as new CEO. Report